الفهرس 
EpidemiologyOnly 14 pages are availabe for public view
 |  | from | 122 |  |  |
| | | from | 122 | | |
Abstract
”AML is the most common acute leukemia in adults. It is characterized by the accumulation of immature myeloid cells in the bone marrow that results in dysfunction of hematopoiesis. AML diagnosis includes not only evaluation of bone marrow and/or peripheral blood (PB) samples, but also cytochemical, immunophenotypic, cytogenetics, and molecular studies. Cytogenetic examination is considered the most important prognostic factor expecting AML outcomes. CLEC12A has recently been identified as an antigen, expressed on leukemic stem cells and leukemic blasts. This expression profile seems stable throughout diagnosis, treatment and relapse on leukemic blasts and leukemic stem cells but not expressed on normal hematopoietic cells making it an attractive target for treatment decreasing the risk of cytopenia associated with chemotherapy. Aim of the study: The current study aimed to demonstrate the expression of CLEC12A in patients with newly diagnosed AML by flow cytometric analysis and explore its relationship with risk factors and prognosis in Egyptian patients with AML. Conclusion: In this study, we found statistical significant expression of CLEC12A in AML patients (p<0.001). However, the expression of CLEC12A appeared similar across FAB subtypes. When comparing AML patients with high CLEC12A expression and those with low expression, we found that OS and DFS were significantly elevated in high CLEC12A group and was associated with statistical significant response (p =0.009) than those with low expression. Key Words ( not more than 10 )AML- CLEC12A- Flowcytometry”